<DOC>
	<DOCNO>NCT00360568</DOCNO>
	<brief_summary>Long term safety efficacy ( 12 month ) levodopa-carbidopa intestinal gel .</brief_summary>
	<brief_title>Safety/Efficacy Study Levodopa-Carbidopa Intestinal Gel Parkinson 's Subjects</brief_title>
	<detailed_description>Study S187.3.003 ( NCT00360568 ) Phase 3 , 12-month , open-label , multicenter continuation treatment study safety , tolerability , efficacy levodopa-carbidopa intestinal gel ( LCIG ) treatment participant levodopa-responsive Parkinson 's disease ( PD ) persistent motor fluctuation despite optimized treatment available PD medication . All participant receive LCIG . Only participant complete 12 week double-blind , double-dummy treatment Study S187.3.001 S187.3.002 ( NCT00357994/ NCT00660387 ) qualify enrollment 12-month continuation treatment study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Idiopathic Parkinson 's disease ( PD ) accord United Kingdon Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria Levodoparesponsive severe motor fluctuation Completion protocol S187.3.001 ( NCT00357994 ) S187.3.002 ( NCT00660387 ) continue meet inclusion criterion precede study Patients medically relevant abnormal finding ( lab , electrocardiogram [ ECG ] , physical examination , adverse event , psychiatric , neurological behavioral disorder , etc . ) end doubleblind phase ( Week 12 ) Study S187.3.001 ( NCT00357994 ) Study S187.3.002 ( NCT00660387 )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>carbidopa</keyword>
	<keyword>severe motor fluctuation</keyword>
	<keyword>intestinal gel</keyword>
	<keyword>levodopa</keyword>
	<keyword>efficacy</keyword>
	<keyword>levodopa carbidopa intestinal gel</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Duodopa</keyword>
	<keyword>levodopa-carbidopa</keyword>
	<keyword>DUOPA</keyword>
</DOC>